Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AVEO Oncology logo — Committed to delivering medicines that provide a better life...

AVEO Oncology

Committed to delivering medicines that provide a better life for patients with cancer.

Founded 2001 United States Boston, United States 197 employees Post Ipo Equity Biotechnology, Health Care +2

General Information

Company Name AVEO Oncology
Founded Year 2001
Location United States Boston, United States +1
Founders / Decision Makers
Team member Team member
Employees 197
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post Ipo Equity
Social

Get notified when AVEO Oncology moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AVEO Oncology

AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company established in 2001. The company's slogan, "Committed to delivering medicines that provide a better life for patients with cancer," reflects its dedication to improving the lives of cancer patients. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. Furthermore, AVEO is actively involved in developing FOTIVDA in immuno-oncology combinations in RCC and other indications, in addition to having other investigational programs in clinical development. Notably, AVEO is committed to fostering diversity, equity, and inclusion within the company. The most recent investment in AVEO Oncology was a Post-IPO Equity investment on 22 March 2021. Although details about the specific investors are not provided, the company's focus on oncology and its track record in delivering medicines for cancer patients underscore its appeal to potential venture capital interests.

Taxonomy: oncology-focused biopharmaceutical, cancer therapeutics, drug development, clinical development, immuno-oncology combinations, proprietary cancer biology platform, targeted cancer therapies, biopharmaceutical company, diversity and inclusion, late-stage biopharmaceutical, commercial-stage, integrated cancer biology, novel cancer therapies, collaborations with pharmaceutical companies

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 22 Mar 2021
Post-IPO Debt •••••• - 10 Aug 2020
Post-IPO Equity •••••• - 15 Jun 2020
Post-IPO Equity •••••• - 28 Mar 2017
Post-IPO Equity •••••• - 13 May 2016

View All 14 Funding Rounds

AVEO Oncology Alternatives & Competitors

AVEO Oncology vs
PharmaMar
PharmaMar Spain

Innovative Oncology

447 employees
Biotechnology, Health Care
AVEO Oncology vs
Kura Oncology, Inc.
Kura Oncology, Inc. United States

Our mission is to realize the promise of precision medicines to help patients with cancer lead bette...

Unknown
315 employees
Biotechnology, Pharmaceutical
Compare AVEO Oncology vs Kura Oncology, Inc.
AVEO Oncology vs
Day One Biopharmaceuticals
Day One Biopharmaceuticals United States

Cancer drug development comes of age.

Post Ipo Equity
190 employees
Biopharma, Biotechnology
Compare AVEO Oncology vs Day One Biopharmaceuticals
Also compare with: AVEO Oncology vs NextCure, Inc. NextCure, Inc.

FAQ About AVEO Oncology

Committed to delivering medicines that provide a better life for patients with cancer.
AVEO Oncology was founded in 2001.
AVEO Oncology is headquartered in Boston, United States.
AVEO Oncology operates in the following industries: Biotechnology, Health Care, Health and Wellness, Pharmaceutical.
AVEO Oncology has approximately 197 employees.
AVEO Oncology has completed 14 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to AVEO Oncology include PharmaMar, Kura Oncology, Inc., Day One Biopharmaceuticals, Cumulus Oncology, NextCure, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AVEO Oncology and PharmaMar are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AVEO Oncology and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy